Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0OQ5R
|
|||
Former ID |
DIB002298
|
|||
Drug Name |
IGN523
|
|||
Drug Type |
Antibody
|
|||
Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [1], [2] | |
Company |
Igenica
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Lymphocyte activation antigen 4F2 (SLC3A2) | Target Info | . | [3] |
KEGG Pathway | Protein digestion and absorption | |||
NetPath Pathway | TCR Signaling Pathway | |||
Pathwhiz Pathway | Kidney Function | |||
Pathway Interaction Database | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
Reactome | Basigin interactions | |||
Amino acid transport across the plasma membrane | ||||
WikiPathways | Transport of inorganic cations/anions and amino acids/oligopeptides | |||
Cell surface interactions at the vascular wall |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT02040506) A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML. U.S. National Institutes of Health. | |||
REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 3 | Antitumor activity of an anti-CD98 antibody. Int J Cancer. 2015 Aug 1;137(3):710-20. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.